{"protocolSection":{"identificationModule":{"nctId":"NCT03631706","orgStudyIdInfo":{"id":"MS200647_0037"},"secondaryIdInfos":[{"id":"2018-001517-32","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"EMD Serono","class":"INDUSTRY"},"briefTitle":"M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)","officialTitle":"An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2025-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-10-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-06-07","type":"ACTUAL"},"completionDateStruct":{"date":"2024-06-25","type":"ACTUAL"},"studyFirstSubmitDate":"2018-08-09","studyFirstSubmitQcDate":"2018-08-13","studyFirstPostDateStruct":{"date":"2018-08-15","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-06-06","resultsFirstSubmitQcDate":"2022-06-06","resultsFirstPostDateStruct":{"date":"2022-06-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-03-21","lastUpdatePostDateStruct":{"date":"2025-04-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"EMD Serono Research & Development Institute, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Merck KGaA, Darmstadt, Germany","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced NSCLC with high PD-L1-tumor expression, with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. The Phase III adaptive design allows for the option to recruit up to 584 patients based on pre-specified rules."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["M7824","Pembrolizumab","PD-L1-tumor Expression","INTR@PID Lung 037","Bintrafusp alfa"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":304,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"M7824","type":"EXPERIMENTAL","interventionNames":["Drug: M7824"]},{"label":"Pembrolizumab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pembrolizumab"]}],"interventions":[{"type":"DRUG","name":"M7824","description":"Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.","armGroupLabels":["M7824"]},{"type":"DRUG","name":"Pembrolizumab","description":"Pembrolizumab: Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.","armGroupLabels":["Pembrolizumab"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC)","description":"Progression free survival was defined as the time from randomization of study intervention until the first documentation of disease progression (PD) or death due to any cause, whichever occurred first. PD: At least a 20 percent (%) increase in the sum of the longest diameter (SLD) taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from randomization of study drug until the first documentation of PD or death, assessed approximately up to 746 days"},{"measure":"Overall Survival (OS)","description":"Overall Survival was defined as the time from randomization of study intervention to the date of death due to any cause. The overall survival was analyzed by using the Kaplan-Meier method.","timeFrame":"Time from randomization of study drug assessed approximately up to 843 days"}],"secondaryOutcomes":[{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0","description":"Adverse Event (AE) was defined any untoward medical occurrence in a participant administered with a study drug, which does not necessarily had a causal relationship with this treatment. Serious AE was defined AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: TEAEs was defined as events with onset date or worsening during the on treatment period. TEAEs included serious AEs and non-serious AEs. Treatment-related TEAEs: reasonably related to the study intervention.","timeFrame":"Time from first treatment assessed up to approximately 843 days"},{"measure":"Percentage of Participants With Unconfirmed Best Overall Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC)","description":"Percentage of participants with unconfirmed best overall response that is at least one overall assessment of complete response (CR) or partial response (PR) reported here.","timeFrame":"Time from randomization of study drug until the first documentation of PD or death, assessed approximately up to 746 days"},{"measure":"Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC)","description":"DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. DOR was determined according to RECIST v1.1 and assessed by IRC. Results were calculated based on Kaplan-Meier estimates.","timeFrame":"From first documented objective response to PD or death due to any cause, assessed approximately up to 746 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed diagnosis of advanced NSCLC\n* Have not received prior systemic therapy treatment for their advanced/Stage four NSCLC. Completion of treatment with cytotoxic chemotherapy, biological therapy, and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease. Confirmation of resolution of toxic effects of previous neoadjuvant/adjuvant chemotherapy therapy to Grade less than or equal to 1. For radiation toxicity or prior major surgeries, participants should have recovered from side effects and/or complications\n* Have measurable disease based on RECIST 1.1\n* Have a life expectancy of at least 3 months\n* Availability of tumor tissue (less than 6 months old) before the first dose is mandatory to determine PD-L1 expression level prior to enrollment\n* PD-L1 high status as determined by central testing\n* Other protocol defined inclusion criteria could apply\n\nExclusion Criteria:\n\n* Participants with nonsquamous NSCLC histologies whose tumor harbors any of the following molecular alterations and targeted therapy is locally approved: epidermal growth factor receptor (EGFR) sensitizing (activating) mutation, anaplastic lymphoma kinase (ALK) translocation, ROS1 rearrangement, or BRAF V600E mutation\n* Has received major surgery within 4 weeks prior to the first dose of study intervention; received thoracic radiation therapy of greater than 30 units of gray (Gy) within 6 months prior to the first dose of study\n* Known severe hypersensitivity to investigational products (M7824 or pembrolizumab), or any components in their formulations\n* Previous malignant disease (other than the target malignancy to be investigated in this study) within the last 3 years\n* Other protocol defined exclusion criteria could apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Responsible","affiliation":"Merck KGaA, Darmstadt, Germany","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Oncology Specialties, PC; Clearview Cancer Institute","city":"Huntsville","state":"Alabama","zip":"35805","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"Cedars Sinai Medical Center - Inflammatory Bowel Disease Center (Clinic","city":"Los Angeles","state":"California","zip":"90048","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"UC Irvine Medical Center","city":"Orange","state":"California","zip":"92868","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"Kaiser Permanente - Harbor City","city":"San Diego","state":"California","zip":"92120","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Sansum Clinic - Santa Barbara","city":"Santa Barbara","state":"California","zip":"93105","country":"United States","geoPoint":{"lat":34.42083,"lon":-119.69819}},{"facility":"Rocky Mountain Cancer Centers - Colorado Springs, N. Nevada","city":"Colorado Springs","state":"Colorado","zip":"80907","country":"United States","geoPoint":{"lat":38.83388,"lon":-104.82136}},{"facility":"Eastern Connecticut Hematology/Oncology Assoc.","city":"Norwich","state":"Connecticut","zip":"06360","country":"United States","geoPoint":{"lat":41.52426,"lon":-72.07591}},{"facility":"Cancer Specialists, LLC - Department of Clinical Research","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Woodlands Medical Specialists","city":"Pensacola","state":"Florida","zip":"32503","country":"United States","geoPoint":{"lat":30.42131,"lon":-87.21691}},{"facility":"The University of Chicago Medical Center","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Decatur Memorial Hospital - Clinical Research","city":"Decatur","state":"Illinois","zip":"62526","country":"United States","geoPoint":{"lat":39.84031,"lon":-88.9548}},{"facility":"Baptist Health Lexington Oncology Associates","city":"Lexington","state":"Kentucky","zip":"40503","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Norton Cancer Institute","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Henry Ford Medical Center","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC - Menorah Medical Center - Oncology Account","city":"Kansas City","state":"Missouri","zip":"64132","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Southeast Nebraska Cancer Center","city":"Lincoln","state":"Nebraska","zip":"68510","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"The Valley Hospital - Luckow Pavilion","city":"Paramus","state":"New Jersey","zip":"07652","country":"United States","geoPoint":{"lat":40.94454,"lon":-74.07542}},{"facility":"University of Rochester Medical Center","city":"Rochester","state":"New York","zip":"14642","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Cleveland Clinic","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"UPMC Cancer Center","city":"Pittsburgh","state":"Pennsylvania","zip":"15232","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"SCRI - Tennessee Oncology","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Vanderbilt University Medical Center","city":"Nashville","state":"Tennessee","zip":"37232","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Texas Oncology - Bedford","city":"Bedford","state":"Texas","zip":"76022","country":"United States","geoPoint":{"lat":32.84402,"lon":-97.14307}},{"facility":"Texas Oncology, P.A. - Sugarland","city":"Sugar Land","state":"Texas","zip":"77479","country":"United States","geoPoint":{"lat":29.61968,"lon":-95.63495}},{"facility":"Virginia Cancer Specialists, PC","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Centro de Oncologia e Investigacion Buenos Aires","city":"Berazategui","zip":"B1880BBF","country":"Argentina","geoPoint":{"lat":-34.76531,"lon":-58.21278}},{"facility":"Instituto Medico Especializado Alexander Fleming","city":"Ciudad Autonoma Buenos Aires","zip":"C1426ANZ","country":"Argentina"},{"facility":"Sanatorio Allende","city":"Córdoba","zip":"X5000JHQ","country":"Argentina","geoPoint":{"lat":-31.40648,"lon":-64.18853}},{"facility":"Instituto Medico Rio Cuarto","city":"Río Cuarto","zip":"5800","country":"Argentina","geoPoint":{"lat":-33.13044,"lon":-64.35272}},{"facility":"Instituto de Oncología de Rosario","city":"Rosario","zip":"S2000KZE","country":"Argentina","geoPoint":{"lat":-32.94682,"lon":-60.63932}},{"facility":"Centro Medico San Roque S.R.L.","city":"San Miguel de Tucumán","zip":"4000","country":"Argentina","geoPoint":{"lat":-26.81601,"lon":-65.21051}},{"facility":"Universitair Ziekenhuis Brussel - Geriatrie","city":"Brussels","zip":"1090","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Jessa Ziekenhuis Hospital","city":"Hasselt","zip":"3500","country":"Belgium","geoPoint":{"lat":50.93106,"lon":5.33781}},{"facility":"UZ Leuven","city":"Pellenberg","zip":"3212","country":"Belgium","geoPoint":{"lat":50.87245,"lon":4.79394}},{"facility":"CHU Mont-Godinne","city":"Yvoir","zip":"5530","country":"Belgium","geoPoint":{"lat":50.3279,"lon":4.88059}},{"facility":"Hospital de Câncer de Barretos - Fundação Pio XII","city":"Barretos","zip":"14784-400","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"CRIO - Centro Regional Integrado de Oncologia","city":"Fortaleza","zip":"60336-045","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"facility":"Hospital São Lucas da PUCRS","city":"Porto Alegre","zip":"90610-000","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"INCA - Instituto Nacional de Câncer","city":"Rio de Janeiro","zip":"20230-230","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"NOB - Núcleo de Oncologia da Bahia","city":"Salvador","zip":"40170-110","country":"Brazil","geoPoint":{"lat":-12.97563,"lon":-38.49096}},{"facility":"CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia - Faculdade de Medicina do ABC","city":"Santo André","zip":"09060-650","country":"Brazil","geoPoint":{"lat":-23.66389,"lon":-46.53833}},{"facility":"Saint John Regional Hospital","city":"Saint John","state":"New Brunswick","zip":"E2L 4L2","country":"Canada","geoPoint":{"lat":45.27076,"lon":-66.05616}},{"facility":"Tom Baker Cancer Centre","city":"Alberta","zip":"T2N 4N2","country":"Canada"},{"facility":"Stronach Regional Cancer Centre - at Southlake","city":"Ontario","zip":"L3Y 2P9","country":"Canada"},{"facility":"Peking University Cancer Hospital","city":"Beijing","zip":"100142","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Guangdong General Hospital","city":"Guangzhou","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Shanghai Cancer Hospital, Fudan University","city":"Shanghai","zip":"200032","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Maison du Ha","city":"Pessac","state":"Gironde","zip":"33604","country":"France","geoPoint":{"lat":44.80565,"lon":-0.6324}},{"facility":"Centre Hospitalier Intercommunal de Créteil - Service de Pneumologie","city":"Créteil","state":"Val De Marne","zip":"94010","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"facility":"Hôpital Nord - AP-HM Marseille# - Service d'Oncologie Multidisciplinaire","city":"Bouches-du-Rhône","zip":"13915","country":"France"},{"facility":"Centre Léon Bérard","city":"Lyon","zip":"69373","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"CHU Rennes - Hopital Pontchaillou - service de pneumologie","city":"Rennes","zip":"35033","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"ICO - Site René Gauducheau","city":"Saint-Herblain","zip":"44805","country":"France","geoPoint":{"lat":47.21154,"lon":-1.651}},{"facility":"CHU de Toulouse - Hôpital Larrey - Service de Pneumologie et Oncologie Pneumologique","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Vivantes Klinikum Am Urban - Haematologie und Onkologie","city":"Berlin","zip":"10967","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Asklepios Fachkliniken Muenchen-Gauting - Abteilung Internistische Onkologie","city":"Gauting","zip":"82131","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"LungenClinic Grosshansdorf","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Medizinische Hochschule Hannover - Pneumologie","city":"Hanover","zip":"30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Universitaetsklinikum Schleswig- Holstein Campus Luebeck","city":"Lübeck","zip":"23538","country":"Germany","geoPoint":{"lat":53.86893,"lon":10.68729}},{"facility":"Universitaetsklinikum Regensburg - Klinik und Poliklinik fuer Innere Medizin II","city":"Regensburg","country":"Germany","geoPoint":{"lat":49.01513,"lon":12.10161}},{"facility":"251 General Air Force Hospital","city":"Athens","zip":"11525","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"General Hospital of Athens of Chest Disease \"SOTIRIA\"","city":"Athens","zip":"11527","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"University General Hospital of Heraklion \"PAGNI\"","city":"Heraklion","zip":"71110","country":"Greece","geoPoint":{"lat":35.32787,"lon":25.14341}},{"facility":"General Hospital Papageorgiou-2nd Department of Dermatalogy","city":"Thessaloniki","zip":"56429","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Princess Margaret Hospital","city":"Hong Kong","zip":"00000","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"The University of Hong Kong","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"The Chinese University of Hong Kong - Emergency Medicine","city":"Shatin","zip":"00000","country":"Hong Kong","geoPoint":{"lat":22.38333,"lon":114.18333}},{"facility":"Azienda Ospedaliera San Giuseppe Moscati - U.O Oncologia Medica","city":"Avellino","zip":"83100","country":"Italy","geoPoint":{"lat":40.91494,"lon":14.79103}},{"facility":"IRCCS Centro di Riferimento Oncologico - Oncologia Medica A","city":"Aviano","zip":"33081","country":"Italy","geoPoint":{"lat":46.07056,"lon":12.59472}},{"facility":"Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi - Oncologia Medica","city":"Bologna","zip":"40138","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"facility":"Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico - Unità Operativa di Oncologia","city":"Catania","zip":"95123","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"facility":"Azienda Ospedaliero Universitaria Mater Domini-Campus Universitario - Centro Oncologico","city":"Catanzaro","zip":"88100","country":"Italy","geoPoint":{"lat":38.88247,"lon":16.60086}},{"facility":"Fondazione IRCCS Istituto Nazionale dei Tumori - Medicina Oncologica I","city":"Milan","zip":"20133","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Università degli studi della Campania Luigi Vanvitelli - Dipartimento di Oncologia","city":"Napoli","zip":"80131","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"facility":"NHO Hokkaido Cancer Center - Dept of Respiratory Medicine","city":"Sapporo","state":"Hokkaido","zip":"003-0804","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"National Cancer Center Hospital - Dept of Respiratory Medicine","city":"Chūōku","zip":"104-0045","country":"Japan","geoPoint":{"lat":33.63867,"lon":130.67068}},{"facility":"Saitama Medical University International Medical Center - Dept of Respiratory Medicine","city":"Hidaka-shi","country":"Japan"},{"facility":"Saitama Cancer Center","city":"Kitaadachigun","zip":"362-0806","country":"Japan"},{"facility":"Cancer Institute Hospital of JFCR - Dept of Respiratory Medicine","city":"Kōtoku","zip":"135-8550","country":"Japan","geoPoint":{"lat":42.50417,"lon":143.14297}},{"facility":"Kurume University Hospital","city":"Kurume-shi","zip":"830-0011","country":"Japan"},{"facility":"Osaka Medical Center for Cancer and Cardiovascular Diseases","city":"Osaka","zip":"541-8567","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Kindai University Hospital","city":"Osakasayama-sh","zip":"589-8511","country":"Japan"},{"facility":"Antoni van Leeuwenhoek Ziekenhuis","city":"Amsterdam","zip":"1066 CX","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"VU Medisch Centrum","city":"Amsterdam","zip":"1081 HV","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Universitair Medisch Centrum Groningen (UMCG) - Parent","city":"Groningen","zip":"9713 GZ","country":"Netherlands","geoPoint":{"lat":53.21917,"lon":6.56667}},{"facility":"Maastricht University Medical Center - Dept of Medical Oncology","city":"Maastricht","zip":"6202 AZ","country":"Netherlands","geoPoint":{"lat":50.84833,"lon":5.68889}},{"facility":"Erasmus Medisch Centrum","city":"Rotterdam","zip":"3015 CE","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"St. Elisabeth Ziekenhuis - Parent","city":"Tilburg","zip":"5022 GC","country":"Netherlands","geoPoint":{"lat":51.55551,"lon":5.0913}},{"facility":"Seoul National University Bundang Hospital","city":"Seongnam-si","state":"Gyeonggi-do","zip":"13620","country":"South Korea","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Chungbuk National University Hospital","city":"Cheongju-si","state":"North Chungcheong","zip":"28644","country":"South Korea","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"Gachon University Gil Medical Center","city":"Incheon","zip":"21565","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Seoul National University Hospital","city":"Seoul","zip":"03080","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Severance Hospital, Yonsei University","city":"Seoul","zip":"03722","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center","city":"Seoul","zip":"06351","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Hospital del Mar - Servicio de Oncologia","city":"Barcelona","zip":"08003","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Quiron Dexeus - Servicio de Oncologia Medica","city":"Barcelona","zip":"08028","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Vall d'Hebron - Dept of Oncology","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"ICO l´Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia","city":"L'Hospitalet de Llobregat","zip":"08908","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"Hospital General Universitario Gregorio Marañon - Servicio de Oncologia Medica","city":"Madrid","zip":"28007","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario 12 de Octubre - Servicio de Oncologia","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Regional Universitario de Malaga","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Hospital Universitario Virgen Macarena - Servicio de Oncologia","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Universitario Virgen del Rocio - Servicio de Oncologia","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Universitari i Politecnic La Fe - Servicio de Oncologia Medica","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Taichung Veterans General Hospital","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"National Taiwan University Hospital","city":"Taipei","zip":"100","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Taipei Veterans General Hospital","city":"Taipei","zip":"11217","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Tri-Service General Hospital","city":"Taipei","zip":"11490","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Adana Numune Training and Research Hospital - Cardiology Department","city":"Adana","zip":"01370","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Dr. Abdurrahman Yurtaslan Oncology Teaching and Research Hospital - Oncology Department","city":"Ankara","zip":"06105","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Trakya University Medical Faculty - Medical Oncology","city":"Edirne","zip":"22030","country":"Turkey (Türkiye)","geoPoint":{"lat":41.67719,"lon":26.55597}},{"facility":"Kocaeli University Research and Application Hospital","city":"Kocaeli","zip":"41380","country":"Turkey (Türkiye)","geoPoint":{"lat":39.62497,"lon":27.51145}},{"facility":"CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU - Ch of Oncology and MR","city":"Dnipro","zip":"49102","country":"Ukraine","geoPoint":{"lat":48.46664,"lon":35.04066}},{"facility":"CI Transcarpathian Cl Onc Center Dep of Surgery#1 SHEI Ivano-Frankivsk NMU - Chair of Oncology","city":"Ivano-Frankivsk","zip":"76018","country":"Ukraine","geoPoint":{"lat":48.92312,"lon":24.71248}},{"facility":"Communal Non-profit Enterprise Regional Center of Oncology - Parent","city":"Kharkiv","zip":"61070","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"facility":"Medical and Preventive Treatment Institution Volyn Regional Oncological Dispensary - Dept of Oncochemotherapy","city":"Lutsk","zip":"43018","country":"Ukraine","geoPoint":{"lat":50.75784,"lon":25.35024}},{"facility":"CCCH City Oncological Center SHEI Uzhgorod NU - Ch of R&O of Faculty of PGE&PUT","city":"Uzhhorod","zip":"88000","country":"Ukraine","geoPoint":{"lat":48.6242,"lon":22.2947}},{"facility":"Medical center \"Oncolife\"","city":"Zaporizhzhia","zip":"69059","country":"Ukraine","geoPoint":{"lat":47.15214,"lon":35.74246}}]},"referencesModule":{"references":[{"pmid":"23886301","type":"RESULT","citation":"Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310."},{"pmid":"37597750","type":"RESULT","citation":"Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon EB, Felip E, Paz-Ares L, Mornex F, Vokes EE, Adjei AA, Robinson C, Sato M, Vugmeyster Y, Machl A, Audhuy F, Chaudhary S, Barlesi F. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. J Thorac Oncol. 2023 Dec;18(12):1731-1742. doi: 10.1016/j.jtho.2023.08.018. Epub 2023 Aug 18."},{"pmid":"38087967","type":"DERIVED","citation":"Milenkovic-Grisic AM, Terranova N, Mould DR, Vugmeyster Y, Mrowiec T, Machl A, Girard P, Venkatakrishnan K, Khandelwal A. Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non-small cell lung cancer based on bintrafusp alfa trials. CPT Pharmacometrics Syst Pharmacol. 2024 Jan;13(1):143-153. doi: 10.1002/psp4.13068. Epub 2023 Dec 13."}],"seeAlsoLinks":[{"label":"Trial Awareness and Transparency website","url":"https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200647_0037"},{"label":"US Medical Information website, Medical Resources","url":"https://medical.emdserono.com/en_US/home.html"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21","infoTypes":["STUDY_PROTOCOL","SAP","CSR","ANALYTIC_CODE"],"timeFrame":"Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union","accessCriteria":"Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.","url":"http://bit.ly/IPD21"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"M7824","description":"Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal."},{"id":"FG001","title":"Pembrolizumab","description":"Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"152"},{"groupId":"FG001","numSubjects":"152"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"151"},{"groupId":"FG001","numSubjects":"152"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"151"},{"groupId":"FG001","numSubjects":"152"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Randomized, not treated","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full analysis set included all participants who were randomized to study intervention.","groups":[{"id":"BG000","title":"M7824","description":"Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal."},{"id":"BG001","title":"Pembrolizumab","description":"Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"152"},{"groupId":"BG002","value":"304"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"67","spread":"9.56"},{"groupId":"BG001","value":"67","spread":"10.17"},{"groupId":"BG002","value":"67","spread":"9.85"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"78"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"110"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"226"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"24"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"138"},{"groupId":"BG002","value":"276"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"105"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"79"},{"groupId":"BG002","value":"170"}]}]},{"title":"Unknown or Not Reported","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"21"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC)","description":"Progression free survival was defined as the time from randomization of study intervention until the first documentation of disease progression (PD) or death due to any cause, whichever occurred first. PD: At least a 20 percent (%) increase in the sum of the longest diameter (SLD) taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"Full analysis set included all participants who were randomized to study intervention.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"months","timeFrame":"Time from randomization of study drug until the first documentation of PD or death, assessed approximately up to 746 days","groups":[{"id":"OG000","title":"M7824","description":"Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal."},{"id":"OG001","title":"Pembrolizumab","description":"Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"152"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","lowerLimit":"0.0","upperLimit":"19.4"},{"groupId":"OG001","value":"11.1","lowerLimit":"0.0","upperLimit":"18.0"}]}]}]},{"type":"PRIMARY","title":"Overall Survival (OS)","description":"Overall Survival was defined as the time from randomization of study intervention to the date of death due to any cause. The overall survival was analyzed by using the Kaplan-Meier method.","populationDescription":"Full analysis set included all participants who were randomized to study intervention.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"months","timeFrame":"Time from randomization of study drug assessed approximately up to 843 days","groups":[{"id":"OG000","title":"M7824","description":"Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal."},{"id":"OG001","title":"Pembrolizumab","description":"Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"152"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.1","lowerLimit":"0.2","upperLimit":"22.1"},{"groupId":"OG001","value":"22.1","lowerLimit":"0.1","upperLimit":"26.4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0","description":"Adverse Event (AE) was defined any untoward medical occurrence in a participant administered with a study drug, which does not necessarily had a causal relationship with this treatment. Serious AE was defined AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: TEAEs was defined as events with onset date or worsening during the on treatment period. TEAEs included serious AEs and non-serious AEs. Treatment-related TEAEs: reasonably related to the study intervention.","populationDescription":"Safety analysis set included all participants who were administered at least one dose of M7824 or Pembrolizumab.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from first treatment assessed up to approximately 843 days","groups":[{"id":"OG000","title":"M7824","description":"Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal."},{"id":"OG001","title":"Pembrolizumab","description":"Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"152"}]}],"classes":[{"title":"Participants with any TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"145"}]}]},{"title":"Participants with any serious TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"61"}]}]},{"title":"Participants with any Treatment Related TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"105"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Unconfirmed Best Overall Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC)","description":"Percentage of participants with unconfirmed best overall response that is at least one overall assessment of complete response (CR) or partial response (PR) reported here.","populationDescription":"Full analysis set included all participants who were randomized to study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from randomization of study drug until the first documentation of PD or death, assessed approximately up to 746 days","groups":[{"id":"OG000","title":"M7824","description":"Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal."},{"id":"OG001","title":"Pembrolizumab","description":"Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"152"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","lowerLimit":"38.6","upperLimit":"55.0"},{"groupId":"OG001","value":"51.3","lowerLimit":"43.1","upperLimit":"59.5"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC)","description":"DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. DOR was determined according to RECIST v1.1 and assessed by IRC. Results were calculated based on Kaplan-Meier estimates.","populationDescription":"Full analysis set included all participants who were randomized to study intervention. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From first documented objective response to PD or death due to any cause, assessed approximately up to 746 days","groups":[{"id":"OG000","title":"M7824","description":"Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal."},{"id":"OG001","title":"Pembrolizumab","description":"Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"78"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Due to small number of events, estimates (Median, lower limit and upper limit) from Kaplan-Meier survival curves could not derive."},{"groupId":"OG001","value":"NA","lowerLimit":"13.5","upperLimit":"NA","comment":"Due to small number of events, estimates (Median and upper limit) from Kaplan-Meier survival curves could not derive."}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Time from first treatment assessed up to approximately 843 days","description":"Safety analysis set included all participants who were administered at least one dose of M7824 or Pembrolizumab.","eventGroups":[{"id":"EG000","title":"M7824","description":"Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.","deathsNumAffected":49,"deathsNumAtRisk":151,"seriousNumAffected":90,"seriousNumAtRisk":151,"otherNumAffected":140,"otherNumAtRisk":151},{"id":"EG001","title":"Pembrolizumab","description":"Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.","deathsNumAffected":43,"deathsNumAtRisk":152,"seriousNumAffected":61,"seriousNumAtRisk":152,"otherNumAffected":135,"otherNumAtRisk":152}],"seriousEvents":[{"term":"Agranulocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Aplastic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Autoimmune haemolytic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Immune thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Iron deficiency anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Cardiopulmonary failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Adrenocorticotropic hormone deficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Autoimmune colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Duodenitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Oesophageal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Oesophageal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Retroperitoneal haematoma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":152}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":151},{"groupId":"EG001","numAffected":7,"numAtRisk":152}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Hyperthermia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Bile duct stone","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Cholestasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Hepatotoxicity","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Bacterial sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Encephalitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":151},{"groupId":"EG001","numAffected":12,"numAtRisk":152}]},{"term":"Pneumonia staphylococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Urinary tract infection bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Fractured sacrum","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":152}]},{"term":"Radiation necrosis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Strangulated incisional hernia","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Troponin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Fluid overload","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":152}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Fracture pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Myopathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Spondylitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Bladder cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Bladder transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Keratoacanthom","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":152}]},{"term":"Squamous cell carcinoma of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Tumour haemorrhage","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Facial paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Immune-mediated encephalitis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":152}]},{"term":"Immune-mediated nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Tubulointerstitial nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":152}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":152}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":152}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Respiratory alkalosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Stridor","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Dermatitis bullous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Erythema multiforme","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Lichen planus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Pemphigoid","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Skin toxicity","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Stevens-Johnson syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Toxic skin eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":152}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":46,"numAtRisk":151},{"groupId":"EG001","numAffected":18,"numAtRisk":152}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":151},{"groupId":"EG001","numAffected":10,"numAtRisk":152}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":151},{"groupId":"EG001","numAffected":23,"numAtRisk":152}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":8,"numAtRisk":152}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":151},{"groupId":"EG001","numAffected":22,"numAtRisk":152}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":151},{"groupId":"EG001","numAffected":24,"numAtRisk":152}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":151},{"groupId":"EG001","numAffected":11,"numAtRisk":152}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":151},{"groupId":"EG001","numAffected":20,"numAtRisk":152}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":151},{"groupId":"EG001","numAffected":10,"numAtRisk":152}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":151},{"groupId":"EG001","numAffected":30,"numAtRisk":152}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":151},{"groupId":"EG001","numAffected":6,"numAtRisk":152}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":151},{"groupId":"EG001","numAffected":26,"numAtRisk":152}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":151},{"groupId":"EG001","numAffected":13,"numAtRisk":152}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":151},{"groupId":"EG001","numAffected":15,"numAtRisk":152}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":151},{"groupId":"EG001","numAffected":21,"numAtRisk":152}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":152}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":151},{"groupId":"EG001","numAffected":4,"numAtRisk":152}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":151},{"groupId":"EG001","numAffected":16,"numAtRisk":152}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":151},{"groupId":"EG001","numAffected":9,"numAtRisk":152}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":151},{"groupId":"EG001","numAffected":14,"numAtRisk":152}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":151},{"groupId":"EG001","numAffected":11,"numAtRisk":152}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":152}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":151},{"groupId":"EG001","numAffected":13,"numAtRisk":152}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":8,"numAtRisk":152}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":151},{"groupId":"EG001","numAffected":16,"numAtRisk":152}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":151},{"groupId":"EG001","numAffected":7,"numAtRisk":152}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":151},{"groupId":"EG001","numAffected":7,"numAtRisk":152}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":151},{"groupId":"EG001","numAffected":26,"numAtRisk":152}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":151},{"groupId":"EG001","numAffected":10,"numAtRisk":152}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":152}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":151},{"groupId":"EG001","numAffected":11,"numAtRisk":152}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":151},{"groupId":"EG001","numAffected":8,"numAtRisk":152}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":151},{"groupId":"EG001","numAffected":8,"numAtRisk":152}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":151},{"groupId":"EG001","numAffected":12,"numAtRisk":152}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":151},{"groupId":"EG001","numAffected":21,"numAtRisk":152}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":151},{"groupId":"EG001","numAffected":13,"numAtRisk":152}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":151},{"groupId":"EG001","numAffected":10,"numAtRisk":152}]},{"term":"Keratoacanthoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":151},{"groupId":"EG001","numAffected":8,"numAtRisk":152}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":151},{"groupId":"EG001","numAffected":14,"numAtRisk":152}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":151},{"groupId":"EG001","numAffected":10,"numAtRisk":152}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":151},{"groupId":"EG001","numAffected":22,"numAtRisk":152}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":151},{"groupId":"EG001","numAffected":18,"numAtRisk":152}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":152}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":151},{"groupId":"EG001","numAffected":6,"numAtRisk":152}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":151},{"groupId":"EG001","numAffected":11,"numAtRisk":152}]},{"term":"Dry Skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":151},{"groupId":"EG001","numAffected":4,"numAtRisk":152}]},{"term":"Hyperkeratosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":152}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":52,"numAtRisk":151},{"groupId":"EG001","numAffected":42,"numAtRisk":152}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":48,"numAtRisk":151},{"groupId":"EG001","numAffected":25,"numAtRisk":152}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":151},{"groupId":"EG001","numAffected":6,"numAtRisk":152}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":151},{"groupId":"EG001","numAffected":5,"numAtRisk":152}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":10,"numAtRisk":152}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":152}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Communication Center","organization":"Merck KGaA, Darmstadt, Germany","email":"service@emdgroup.com","phone":"+49-6151-72-5200"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-06-22","uploadDate":"2022-06-06T15:15","filename":"Prot_000.pdf","size":14794144},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2021-07-14","uploadDate":"2022-06-06T15:15","filename":"SAP_001.pdf","size":6204169}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582435","term":"pembrolizumab"}]}},"hasResults":true}